Emerging treatments
Complement activation inhibitors
A number of biological agents that inhibit various stages of complement activation are being evaluated in patients with GBS.[172] Eculizumab, a humanised monoclonal antibody that specifically binds to complement component 5, did not reach the pre-defined response rate in one small phase 2 randomised clinical trial of patients with severe GBS.[173][174]
Other therapies
Small controlled trials of interferon beta-1a, brain-derived neurotrophic factor, and cerebrospinal fluid filtration failed to demonstrate significant benefit in patients with acute GBS.[175]
[ 
]
One Chinese herbal product, tripterygium polyglycoside, hastened recovery compared with corticosteroids; however, given that corticosteroids are not usually beneficial in GBS, the significance of this finding is unclear.[175] Imlifidase, a cysteine protease derived from the IgG‑degrading enzyme of Streptococcus pyogenes, is being investigated for GBS.[176][177]
Use of this content is subject to our disclaimer